Mitchell Finer, PhD

Executive Partner, MPM Capital

Mitchell (Mitch) Finer is a co-founder of CODA Biotherapeutics and the company’s initial CEO.  He is an executive partner at MPM Capital, and serves on several company Boards including those of Oncorus (Chairman), Adverum Biotechnologies, Semma Therapeutics and TCR2.  Previously, Mitch was co-founder and initial CEO of oncolytic virus company Oncorus.  He served as CSO of bluebird bio, where he was responsible for the strategic build of bluebird’s gene-modified adult hematopoietic stem cell therapy business and led the strategic development and partnering of BLUE’s CART and genome engineering programs.  He also served as CEO of Intracel Corporation and Genteric, Inc, Vice President of Research for Cell Genesys and the Gencell division of Aventis Pharma (now Sanofi) and Senior Vice President of Development at Novacell (now Viacyte). 

Mitch received his Ph.D. in Biochemistry and Molecular Biology from Harvard University and a B.S. in biochemistry and microbiology from the UC, Berkeley. He completed a post-doctoral fellowship at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology (MIT).